Our global life sciences company brings diagnostic testing & drug development together.
If both tissue flow cytometry and histology are required, submit one portion of fresh specimen in transport medium or saline for flow cytometry and one portion in 10% formalin for histologic analysis.
Please direct any questions regarding this test to oncology customer service at 800-345-4363. Pathologist consultation is available Monday through Friday. Indicate differential diagnosis on test request form. Submit recent CBC results for consideration in report. Billing will be performed back end.
1 - 3 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
For more information, please view the literature below.
Whole blood, bone marrow aspirate, body fluids, fresh lymph node, spleen, extranodal solid tissue, biopsy, or needle aspirate
3 mL whole blood or 2 mL bone marrow aspirate, 2 mL body fluid tube. Large volumes of body fluids should be concentrated to <5 mL; 0.5 to 1.0 cm3 fresh tissue.
1 mL whole blood or bone marrow (Note: This volume does not allow for repeat testing.)
Green-top (sodium heparin) tube (preferred), lavender-top (EDTA) tube, or yellow-top (ACD) tube for whole blood or bone marrow (acceptable, not preferred); lavender-top (EDTA body fluids) tube; fresh tissue in lymph node transport bottle containing RPMI
Note: In an attempt to maintain specimen at room temperature,
• In hot weather, enclose a refrigerated (not frozen) gel pack in shipper kit.
• In cold weather, run hot water over gel pack for three to five minutes and enclose in shipper kit.
• Ship specimens in a timely manner based on the specific requirements of the test.
Submit blood or bone marrow at room temperature. Collect the specimen so it will arrive in the laboratory Monday through Saturday and within 24 hours of collection. Please state on the test request form the date and time of collection and the name and phone number of the pathologist responsible for the histologic or cytologic diagnosis.
For fresh tissue, aseptically cut tissue in pieces and place in lymph node transport bottle. If aspirate is submitted, rinse needle in transport medium. Submit at room temperature using Lymph Node Transport Kit (supplied by LabCorp). If transport kit is not available, place specimen in sterile container with saline. Submit specimen so it will arrive in the laboratory Monday through Saturday and within 24 hours of surgical removal. To avoid transportation delays, submit specimen on the day of collection.
Non-New York state specimens: Maintain specimen at room temperature. New York state specimens: Ship with a refrigerated (not frozen) gel pack in shipper kit.
Hemolysis; specimen clotted; specimen frozen; specimen in formalin or other fixative; blood (non-New York state specimens) more than 72 hours old; blood (New York state specimens) more than 48 hours old; bone marrow aspirates more than five days old; bags or bottles of body fluid or bronchial washing; tissue in formalin or other fixative; contaminated transport medium
Identify and characterize the following:
• Reactive lymphocytosis vs chronic lymphocytic leukemia (CLL)
• CLL vs mantle cell lymphoma
• Prolymphocytic leukemia vs lymphoblastic leukemia large granular lymphocyte proliferations, T-γ lymphoproliferative disease, natural killer cell proliferations, T-cell CLL, T-cell γ/δ proliferations
• Sézary syndrome
• Non-Hodgkin lymphoma
• Adult T-cell leukemia/lymphoma
Neoplastic B-cell proliferations (chronic leukemias and lymphomas) are clonal expansions of cells that express either κ or λ immunoglobulin light chains.
Immunophenotyping by flow cytometry
In normal or reactive processes, a bimodal distribution of κ- and λ-positive B cells is present in a ratio of approximately 1.5:1. Immunophenotyping using multiparameter analysis (simultaneous staining with a pan B-cell marker and anti-immunoglobulin light chain antibodies) is a rapid and specific method for detecting and confirming the presence of neoplastic B-cell disorders.
Chronic lymphocytic leukemia (CLL) is a clonal lymphoproliferative disorder usually of B-cell origin (95%), that has been traditionally diagnosed using clinical and morphologic criteria. Incorporation of immunophenotypic features into the diagnostic criteria is helpful in separating common B-cell CLL from other lymphoproliferative disorders. Detection of karyotypic abnormalities is useful in assessing prognosis. Lymphocytes in B-CLL coexpress CD19, CD20, and CD23 pan B-cell antigens, CD5, pan T-cell antigen, and a single immunoglobulin light chain, κ or λ. CD10 (CALLA) expression is usually absent. Mantle cell lymphoma is distinguished from CLL by absent or very dim expression of CD23.
Lymphomas are biologically complex neoplasms of the immune system. Numerous classification schemes have been developed based on morphologic features. This limited approach is often unreliable. Immunophenotyping, by flow cytometry and/or immunohistochemistry, has emerged as a valuable adjunct to conventional morphologic diagnosis and classification. Flow cytometry offers the advantage of rapid multiparameter analysis. Combining light scatter characteristics with patterns of antigen expression and DNA content provides biological information that is useful in making a diagnosis and assessing prognosis. Various gating strategies can be employed to enhance the detection of minor populations, thus providing a level of sensitivity comparable to molecular methods (gene rearrangement studies).
T-cell CLL, unlike B-CLL, is associated with rapid onset, an aggressive clinical course poorly responsive to therapy and decreased survival. Immunophenotyping, in the majority of cases, demonstrates expression of CD3 (a pan T-cell antigen), and CD4 (the helper cell antigen). CD8 (the suppressor/cytotoxic cell antigen) is usually not expressed. Genotyping demonstrates a clonal rearrangement of the T-cell receptor gene.
Large granular lymphocyte (LGL) proliferations can be divided into T-cell and natural killer (NK) cell subsets by immunophenotyping. The more common T-cell type expresses CD3, a pan T-cell antigen and CD8, the suppressor/cytotoxic cell antigen. Genotyping demonstrates a rearrangement of the T-cell receptor gene. The NK cell type is relatively rare and expresses CD2 and CD16 and/or CD56. CD3 expression is absent. Genotyping demonstrates a germline configuration of the T-cell receptor gene.
In Sézary syndrome, the neoplastic lymphocytes are T cells with a helper cell phenotype. Expression of CD7, a pan T-cell antigen, is absent and is useful in distinguishing the neoplastic cells from normal T-helper cells. Genotyping demonstrates a clonal rearrangement of the T-cell receptor gene.
In adult T-cell leukemia/lymphoma, the neoplastic lymphocytes are T-cells with a helper cell phenotype. Expression of CD3, CD4, and CD25 is present. Expression of CD7 is absent. Genotyping demonstrates a clonal rearrangement of the T-cell receptor gene.
Detection of a B-cell population coexpressing CD22, CD11c, and CD25 is useful in establishing a diagnosis of hairy cell leukemia when used in conjunction with morphology and cytochemistry. Immunophenotyping by flow cytometry is a sensitive method for detecting residual or recurrent disease in the peripheral blood of patients with an established diagnosis.
Detection of a population of cells expressing CD38 and CD138 in the peripheral blood is useful in establishing a diagnosis of plasma cell leukemia when used in conjunction with morphology.
Lineage assignment in acute leukemia is necessary for selecting appropriate therapy and is useful in assessing prognosis. Multiparameter analysis using four-color immunophenotyping techniques is a rapid and specific method of assigning lineage in acute leukemia.
This profile is also useful in distinguishing lymphoid from myeloid blast crisis in CML and immunophenotyping lymphoblastic lymphoma in blood or bone marrow. Immunophenotyping and cytogenetic analysis are increasingly being used to supplement the traditional methods (morphology and cytochemistry) of classifying acute leukemias and to provide prognostic information. Acute lymphoblastic leukemia (ALL) can be classified into undifferentiated null T- and B-cell lineages. In all of B-cell lineage, expression of CD10 (CALLA) is a favorable prognostic factor. Acute myelogenous leukemias (AML) are a heterogeneous group. In cases where morphology and cytochemical staining is equivocal, immunophenotyping can be useful. Immunophenotyping is particularly useful in classifying megakaryoblastic leukemia (FABM7). A combination of characteristic light scattering properties and myeloid phenotype can suggest a diagnosis of acute promyelocytic leukemia (FABM3). Confirmation of the retinoic acid receptor gene rearrangement by cytogenetic or molecular methods is recommended. See tests listed under Related Information and related FISH tests (eg, 510669).
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|480260||Comp panel: Leukemia/Lymphoma||490024||Flow Interpretation||50595-8|
|480260||Comp panel: Leukemia/Lymphoma||490025||Flow Comment||48767-8|
|480260||Comp panel: Leukemia/Lymphoma||490026||Lab Case Number||N/A|
|480260||Comp panel: Leukemia/Lymphoma||490045||Clinical Information||55752-0|
|480260||Comp panel: Leukemia/Lymphoma||490027||Specimen Type||31208-2|
|480260||Comp panel: Leukemia/Lymphoma||490028||Assessment of Leukocytes||N/A|
|480260||Comp panel: Leukemia/Lymphoma||490031||Cellularity Assessment||67127-1|
|480260||Comp panel: Leukemia/Lymphoma||490032||Viability||33194-2|
|480260||Comp panel: Leukemia/Lymphoma||490033||Immunophenotypic Profile||67128-9|
|480260||Comp panel: Leukemia/Lymphoma||490035||Analysis and Gating Strategy||N/A|
|480260||Comp panel: Leukemia/Lymphoma||490036||Phenotype Chart||55230-7|
|480260||Comp panel: Leukemia/Lymphoma||490052||Reagents Used:||N/A|
|480260||Comp panel: Leukemia/Lymphoma||490039||Resulting Path Name||19139-5|
|480260||Comp panel: Leukemia/Lymphoma||490040||Clinician provided ICD10:||52797-8|
|480260||Comp panel: Leukemia/Lymphoma||490041||Resulting ICD10:||52797-8|
|480260||Comp panel: Leukemia/Lymphoma||490042||Indications for Study||42349-1|
|480260||Comp panel: Leukemia/Lymphoma||490046||Comment:||77202-0|
|480260||Comp panel: Leukemia/Lymphoma||481641||80563-0|
|480260||Comp panel: Leukemia/Lymphoma||480059||Flow LLS Tracking||N/A|
|480260||Comp panel: Leukemia/Lymphoma||489123||LS Monitor||N/A|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf